In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $43.00. The company’s shares closed ...

WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the ...

PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The company reported a “beat and raise” in Q3 and its ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to treat a potential fatal enzyme deficiency disorder, the company said on ...

WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) stands at a critical juncture as it navigates a transformative period in its journey as a biopharmaceutical company focused on rare disorders. With a robust ...

Revenue: US$196.8m (flat on 3Q 2023). Net loss: US$106.7m (loss narrowed by 20% from 3Q 2023). US$1.39 loss per share (improved from US$1.76 loss in 3Q 2023). Revenue exceeded analyst estimates by ...